Patents Assigned to ONO
-
Patent number: 10673060Abstract: Provided is a roll-press machine provided with a wrinkle occurrence prevention device for suppressing occurrence of wrinkles caused by a roll-pressing operation on a coated part and an uncoated part of an electrode plate, and a roll-pressing method. A work roll having a diameter smaller than that of the pressing roll is pressed to allow the uncoated part to be rolled between the pressing roll and the work roll, and the work roll is held by two backup rolls arranged in a V-shape formation so that the work roll can press the uncoated part with a pressing force uniform width-wise.Type: GrantFiled: February 27, 2017Date of Patent: June 2, 2020Assignee: Ono Roll Co., Ltd.Inventors: Katsuhiko Yanai, Shigeru Mori
-
Publication number: 20200157050Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: ApplicationFiled: January 24, 2020Publication date: May 21, 2020Applicant: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro YASHIRO, Daisuke WAKAMATSU, Tetsuji SAITO
-
Patent number: 10647770Abstract: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 ?g/kg, and (c) without requiring administration for at least 3 months after the last administration.Type: GrantFiled: June 9, 2017Date of Patent: May 12, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro Shibayama, Masamichi Imai
-
Publication number: 20200138945Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.Type: ApplicationFiled: October 11, 2019Publication date: May 7, 2020Applicants: E.R. SQUIBB & SONS, L.L.C., Ono Pharmaceutical Co., LTD.Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
-
Publication number: 20200140435Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.Type: ApplicationFiled: December 19, 2019Publication date: May 7, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Motoyuki TANAKA, Takashi KONDO, Yasuo HIROOKA, Taihei NISHIYAMA, Atsushi HIRAMATSU, Tomoyuki KODA, Sho KOUYAMA
-
Patent number: 10617667Abstract: Disclosed are a method for treating brain tumors, as well as a medicament for treating brain tumors. Provided is a medicament for treating brain tumors, the medicament containing a combination of 4-[4-cyano-2-({[(2?R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1?-cyclopropan]-2?-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof, and an anti-PD-1 antibody. The combination exhibits an excellent effect for treating brain tumors, and is thus useful to treat brain tumors.Type: GrantFiled: October 31, 2018Date of Patent: April 14, 2020Assignees: ONO PHARMACEUTICAL CO., LTD., The Regents of The University of CaliforniaInventors: Hideho Okada, Tohru Kotani, Kazuhiko Takeda
-
Publication number: 20200102284Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation is disclosed. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.Type: ApplicationFiled: December 2, 2019Publication date: April 2, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Masaki ASADA, Kousuke TANI, Masaya HIROBE, Satonori HIGUCHI, Kazuhiro FUCHIBE, Ryo OIKAWA, Tohru KOTANI, Hirotsugu TAKANO
-
Publication number: 20200093781Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.Type: ApplicationFiled: November 27, 2019Publication date: March 26, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
-
Patent number: 10576122Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.Type: GrantFiled: April 14, 2019Date of Patent: March 3, 2020Assignees: Helsinn Healthcare SA, Ono Pharmaceutical Co., Ltd.Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor de Groot, Silvina Garcia Rubio, Peter Manini
-
Publication number: 20200062846Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.Type: ApplicationFiled: July 1, 2019Publication date: February 27, 2020Applicants: ONO PHARMACEUTICAL CO., LTD.Inventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
-
Patent number: 10570093Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: GrantFiled: August 9, 2018Date of Patent: February 25, 2020Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
-
Publication number: 20200048256Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: ApplicationFiled: October 16, 2019Publication date: February 13, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Patent number: 10550119Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.Type: GrantFiled: July 31, 2019Date of Patent: February 4, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Motoyuki Tanaka, Takashi Kondo, Yasuo Hirooka, Taihei Nishiyama, Atsushi Hiramatsu, Tomoyuki Koda, Sho Kouyama
-
Patent number: 10538502Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.Type: GrantFiled: July 18, 2018Date of Patent: January 21, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Masaki Asada, Kousuke Tani, Masaya Hirobe, Satonori Higuchi, Kazuhiro Fuchibe, Ryo Oikawa, Tohru Kotani, Hirotsugu Takano
-
Publication number: 20200000816Abstract: A somatostatin receptor subtype 2 agonist represented by the general formula (I): wherein all symbols have the same meanings as described in the specification, or a salt thereof, which can be easily administered and can alleviate pain accompanied by the therapy of patients.Type: ApplicationFiled: February 7, 2018Publication date: January 2, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akiharu ISHIDA, Atsushi YOSHIDA, Hidenori MIYATA, Tomoyuki SHONO
-
Publication number: 20200002313Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: ApplicationFiled: August 14, 2019Publication date: January 2, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki INUKAI, Jun TAKEUCHI, Tomoko YASUHIRO
-
Publication number: 20200000810Abstract: The present invention relates to a Brk inhibitory compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug of any of these.Type: ApplicationFiled: December 20, 2017Publication date: January 2, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Masakuni KURONO, Atsushi YOSHIDA, Shingo HOTTA
-
Patent number: 10519105Abstract: An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).Type: GrantFiled: April 21, 2017Date of Patent: December 31, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Kentaro Yashiro, Masashi Kato, Tetsuji Saito, Takuya Okada, Daisuke Wakamatsu, Adam James Davenport, Christopher Charles Stimson
-
Publication number: 20190389837Abstract: The present invention relates to an ethane-sulfonate salt of N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, which has an Axl-inhibiting activity and is useful as a prophylactic and/or therapeutic agent for immune diseases, cancer and the like, a crystal thereof, and a pharmaceutical composition thereof.Type: ApplicationFiled: January 25, 2018Publication date: December 26, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Takahiro NEKADO, Hideomi KIJIMA, Shizuka ONO, Toshihiko NISHIYAMA
-
Patent number: 10501442Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: GrantFiled: December 31, 2018Date of Patent: December 10, 2019Assignee: ONO PHARMACEUTICALS CO., LTD.Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro